Cannabidiol is under clinical development by CannaLean Biotechs and currently in Phase II for Hyperlipidemia. According to GlobalData, Phase II drugs for Hyperlipidemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cannabidiol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cannabidiol is under development for the treatment of hyperlipidemia.
For a complete picture of Cannabidiol’s drug-specific PTSR and LoA scores, buy the report here.